Share ownership Chugai Pharmaceutical Co., Ltd.

4519

JP3519400000

Pharmaceuticals

Delayed Japan Exchange Other stock markets 14:30:00 12/03/2026 HKT			5-day change	1st Jan Change
9,429.00 ^JPY	-0.38%		-3.06%	+14.39%

02-24	Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in Japan	CI
02-24	Sarepta Therapeutics Says Elevidys Available in Japan for Duchenne Muscular Dystrophy	MT

Share class: Chugai Pharmaceutical Co., Ltd.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	1,679,057,667	639,559,233 ( 38.09 %)	33,531,864 ( 1.997 %)	38.09 %

Major shareholders: Chugai Pharmaceutical Co., Ltd.

Name	Equities	%	Valuation
ROCHE HOLDING AG 59.89 %	1,005,670,000	59.89 %	67 345 M ¥
CHUGAI PHARMACEUTICAL CO., LTD. 1.986 %	33,354,300	1.986 %	2 234 M ¥
Sumitomo Life Insurance Co. 0.5481 %	9,203,000	0.5481 %	616 M ¥
TOKIO MARINE HOLDINGS, INC. 0.1692 %	2,840,487	0.1692 %	190 M ¥
RBC Global Asset Management (Asia) Ltd. 0.0812 %	1,363,913	0.0812 %	91 M ¥
Sumitomo Mitsui Trust Asset Management Co., Ltd. 0.0756 %	1,269,500	0.0756 %	85 M ¥
State Street Global Advisors Ltd. 0.0652 %	1,095,184	0.0652 %	73 M ¥
Sjunde AP-fonden 0.056 %	940,300	0.056 %	63 M ¥
Pictet Asset Management Ltd. 0.055 %	923,400	0.055 %	62 M ¥
Guardians of New Zealand Superannuation 0.038 %	637,313	0.038 %	43 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Confluence Investment Management LLC 0.001351 %	45,369	0.001351 %	2 M ¥
RhumbLine Advisers LP 0.001322 %	44,380	0.001322 %	1 M ¥
Sterling Capital Management LLC 0.001311 %	44,024	0.001311 %	1 M ¥
GAMMA Investing LLC 0.000377 %	12,645	0.000377 %	423 393 ¥
PNC Wealth Management LLC 0.000314 %	10,551	0.000314 %	353 279 ¥
Riverbridge Partners LLC 0.000233 %	7,825	0.000233 %	262 004 ¥
Ancora Private Wealth Advisors LLC 0.000039 %	1,305	0.000039 %	43 695 ¥
Salomon & Ludwin LLC 0.000017 %	577	0.000017 %	19 320 ¥
Hantz Financial Services, Inc. 0.000009 %	297	0.000009 %	9 944 ¥
Thurston, Springer, Miller, Herd & Titak, Inc. 0.000008 %	256	0.000008 %	8 572 ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Roche Holding AG	59.9%
Chugai Pharmaceutical Co., Ltd.	1.99%
Institutional	0.89%
Other	0.55%
Tokio Marine Holdings, Inc.	0.17%
Sompo Holdings, Inc.	0.01%
Techno Ryowa Ltd.	0.01%
Unknown	36.48%

Based on 1000 largest holdings

Geographical origin of shareholders

Switzerland	59.93%
Japan	2.92%
United Kingdom	0.21%
Hong Kong	0.09%
Sweden	0.08%
Ireland	0.06%
New Zealand	0.04%
Norway	0.03%
France	0.02%
Canada	0.02%
Finland	0.02%
Spain	0.02%
United States	0.02%
Germany	0.01%
Singapore	0.01%
Luxembourg	0.01%
Austria	0.01%
Denmark	0.01%
Australia	0.01%

Based on 1000 largest holdings

Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.

Employees

5,026

Sector

Pharmaceuticals

Calendar

04-24 - Earnings release - Q1 2026

More about the company